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Background. Puumala orthohantavirus (PUUV) causes hemorrhagic fever with renal syndrome (HFRS). Patients with HFRS 
have an activated coagulation system with increased risk of disseminated intravascular coagulation (DIC) and venous thromboem-
bolism (VTE). The aim of the study was to determine whether circulating extracellular vesicle tissue factor (EVTF) activity levels 
associates with DIC and VTE (grouped as intravascular coagulation) in HFRS patients.
Methods. Longitudinal samples were collected from 88 HFRS patients. Patients were stratified into groups of those with intra-
vascular coagulation (n = 27) and those who did not (n = 61). We measured levels of circulating EVTF activity, fibrinogen, activated 
partial prothrombin time, D-dimer, tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), and platelets.
Results. Plasma EVTF activity was transiently increased during HFRS. Levels of EVTF activity were significantly associated 
with plasma tPA and PAI-1, suggesting that endothelial cells could be a potential source. Patients with intravascular coagulation had 
significantly higher peak EVTF activity levels compared with those who did not, even after adjustment for sex and age. The peak 
EVTF activity value predicting intravascular coagulation was 0.51 ng/L with 63% sensitivity and 61% specificity with area under the 
curve = 0.63 (95% confidence interval, 0.51–0.76) and P = .046.
Conclusions. Plasma EVTF activity during HFRS is associated with intravascular coagulation.
Keywords.  disseminated intravascular coagulation; hemorrhagic fever with renal syndrome; orthohantavirus; thrombosis; 
tissue factor.
Viral hemorrhagic fevers are associated with activation of co-
agulation. They are caused by several distinct families of vir-
uses, Arenaviridae, Hantaviridae, Phenuiviridae, Nairoviridae, 
Filoviridae, and Flaviviridae, which are all single-stranded ri-
bonucleic acid viruses and rely on an animal or insect hosts 
as their natural reservoir [1]. Orthohantaviruses belong to the 
Hantaviridae family and cause 2 different clinical syndromes 
depending on the virus species [2, 3]. Puumala orthohantavirus 
(PUUV), primarily located in Europe and Asia, causes hemor-
rhagic fever with renal syndrome (HFRS) that is characterized 
by endothelial activation, coagulation disturbances, and kidney 
injury [4]. Orthohantaviruses in the Americas, most notably Sin 
Nombre virus, cause hantavirus cardiopulmonary syndrome 
(HCPS) [5]. Sin Nombre virus infection-associated HCPS is 
characterized by the development of severe non-cardiogenic 
pulmonary edema, respiratory failure, cardiogenic shock, and 
has a high case-fatality rate approaching 35% [6]. However, re-
cent studies have shown that HFRS can also present with pul-
monary symptoms indicating similarities between the 2 clinical 
syndromes [7, 8].
Circulating extracellular vesicles (EVs), also known as 
microparticles or microvesicles, are small membrane fragments 
released from activated or apoptotic cells [9]. Tissue factor (TF) 
is the receptor for factor VII/VIIa and is essential for hemostasis 
[10]. Tissue factor-positive EVs (EVTF) are highly procoagulant 
and can be used as a biomarker of pathologic intravascular TF 
expression [11]. Aberrant TF expression appears to be the pri-
mary pathophysiologic mechanism of activation of coagulation 
during viral infection [12]. Indeed, TF is the major activator of 
coagulation in hemorrhagic fever viruses, including Ebola and 
dengue virus [13, 14]. Of note, we recently showed increased 
EVTF activity levels in HCPS patients [15]. Increased expres-
sion of TF can lead to both arterial and venous thrombosis [16].
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Our previous study showed HFRS patients had low platelet 
levels, increased platelet activation, and dysregulated fibrinol-
ysis [17]. In addition, approximately 30% of HFRS patients were 
shown to fulfill modified criteria for disseminated intravascular 
coagulation (DIC) [18]. We have also identified HFRS as a risk 
factor for both arterial and venous thromboembolic events, 
such as acute myocardial infarction, stroke, deep vein throm-
bosis, and pulmonary embolism [19, 20]. However, the factors 
that contribute to this increased thrombosis risk in patients 
with orthohantavirus infections are poorly understood. Of in-
terest, PUUV infection of human endothelial cells induced TF 
and plasminogen activator inhibitor 1 (PAI-1) expression [21]. 
Insights from the study of other related hemorrhagic fever vir-
uses suggest that TF likely serves as a critical initiator of coag-
ulation in this setting [22]. Therefore, we sought to determine 
whether PUUV-associated HFRS leads to increased levels of 
plasma EVTF activity and activation of coagulation resulting in 
DIC and venous thromboembolism (VTE).
METHODS
Hemorrhagic Fever With Renal Syndrome Patients
All patients with a clinical picture of HFRS and diagnosed with 
PUUV infection that accepted participation in the study were 
included. These patients had initial contact with the outpatient 
and/or inpatient Infectious Disease clinic at the University 
Hospital of Umeå, Sweden. Diagnosis of PUUV infection was 
established for all patients by presence of PUUV-specific im-
munoglobulin (Ig)M and IgG antibodies in patient serum 
using immunofluorescence assay [23]. In brief, diagnosis of 
PUUV infection was performed by addition of patient sera to 
slides that were covered with Vero E6 cells, which had been 
infected with the local strain PUUV Umeå/hu. To detect IgM, 
the patient sera were treated with rheumatoid factor-absorbent 
(Virion/Serion GmbH, Würzburg, Germany). This was per-
formed to avoid potential interference by rheumatoid factor. 
This was followed by determination of PUUV-specific anti-
bodies by use of fluorescein-conjugated rabbit antihuman IgM, 
IgA, and IgG (F0317, F0204, and F202, respectively; DAKO 
A/S, Glostrup, Denmark). After positive PUUV diagnosis, pe-
ripheral venous blood samples were collected at first contact 
and approximately twice a week during HFRS. Patients with 
HFRS were either treated as hospitalized patients or via the 
outpatient clinic, and, after discharge, the patients returned 
at specific designated time points to the outpatient clinic for 
clinical assessment and blood sampling. A  final convalescent 
blood sample was taken at last follow-up time point (conva-
lescence). The blood samples were centrifuged and plasma 
fraction aliquoted followed by storage at −80°C until analysis. 
Patients were stratified into groups of those who had had in-
travascular coagulation or not. According to a previous study 
of cancer patients, DIC predicted VTE [24]. Therefore, we de-
fined intravascular coagulation in patients for those who had 
had a VTE during HFRS or fulfilled criteria for DIC according 
to criteria previously published [18].
Ethical approval was granted by the Regional Ethics Review 
Board at Umeå University, Umeå, Sweden, and all patients gave 
informed and signed consent.
Clinical Assays
Blood samples obtained from HFRS study participants (Umeå 
University Hospital) were assessed for D-dimer, activated par-
tial thromboplastin time (APTT), fibrinogen, platelet counts, 
and creatinine according to routine procedures at the accred-
ited Clinical Chemistry Laboratory, Umeå University Hospital.
Coagulation and Fibrinolysis Assays
Levels of plasma EVTF activity were measured using a factor 
X (FXa) generation assay [25]. Based on a previous study, we 
defined a positive sample to be ≥0.21 ng/L [26]. Levels of PAI-1 
antigen and tissue plasminogen activator (tPA) antigen were 
analyzed in HFRS patient plasma samples using commercially 
available enzyme-linked immunosorbent assay kits (Biopool, 
Umeå, Sweden).
Statistical Analysis
The median peak levels and interquartile range (IQR) of 
EVTF, tPA, PAI-1, D-dimer, APTT, fibrinogen, and creati-
nine and nadir level of platelets during HFRS (within 21 days 
postdisease onset [DPDO]) are shown. Samples collected at 
different time points during HFRS were pooled into the time 
groupings according to DPDO: 0–3, 4–6, 7–9, 10–12, 13–15, 
16–18, 19–21, 22–30, and follow-up (the latest sample obtained 
for each patient). The mean and standard error of the mean 
(SEM) are calculated at different time groupings of EVTF, 
tPA, PAI-1, D-dimer, APTT, fibrinogen, and platelets during 
HFRS using the generalized estimating equation (GEE) as-
suming exchangeable correlation structure between repeated 
observation. Patients with HFRS were stratified into 2 equal-
sized groups based on the median age, and the effects of age 
and sex on peak EVTF were analyzed using the generalized 
linear model. Furthermore, whether the age at disease onset 
differed between those who fulfilled DIC criteria or had a 
VTE compared with those who did not was calculated using 
the Mann-Whitney U test. The difference between the levels 
of markers during early HFRS (<21 DPDO) compared with 
late HFRS (21–30 DPDO) is calculated using the GEE method. 
Furthermore, the peak EVTF activity during HFRS (peak value 
within 21 DPDO) was compared with follow-up (latest sample 
obtained from each patient) using the non-parametric related 
samples Wilcoxon signed-rank test. The association between 
EVTF activity, coagulation (thrombocytes, fibrinogen, APTT), 
and fibrinolysis (D-dimer, tPA, PAI-1) markers for HFRS pa-
tients was analyzed using the GEE method. Only time points 
within 21 DPDO were included in this analysis. The general-
ized linear model was used to compare the mean and SEM of 
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peak EVTF levels (0–21 DPDO) between HFRS patients who 
had had an intravascular coagulation (either fulfilled DIC cri-
teria or those who had had a VTE) versus those who did not. 
The level of EVTF activity that predicted intravascular coag-
ulation was analyzed using a receiver operating characteristic 
(ROC) curve analysis yielding area under the curve (AUC) 
with 95% confidence intervals (CIs).
The level of significance was set to P < .05. The statistical ana-
lyses were performed using SPSS version 25 (IBM).
RESULTS
Patient Characteristics
The study group included 88 HFRS patients whose dem-
ographics and clinical characteristics are shown in Table 
1. A  total of 410 samples were collected ranging from early 
HFRS to follow-up, where the latest follow-up sample was 
obtained at median 92 DPDO (IQR, 66–132). Of these pa-
tients, 67 were hospitalized and spent a median of 5 days in 
the hospital. The median age was 52  years at disease onset 
(IQR, 40.3–63).
There were 27 (30.7%) patients with intravascular coagu-
lation (1 VTE patient; 2 VTE and DIC patients; and 24 DIC 
patients). The 3 patients (all female) who had a VTE within 
21  days of disease onset had mesenteric venous thrombosis 
(previously described in a case report [27]), lower extremity 
deep vein thrombosis, and pulmonary embolism. One patient 
developed VTE after discharge, and diagnosis of the VTE was 
performed at a follow-up where the patient had already had 
symptoms several days prior. Therefore, the exact date of VTE 
occurrence is unknown, and it is not possible to score for DIC 
due to lacking laboratory data in this time period. The age did 
not differ significantly between patients who had had intravas-
cular coagulation and those who did not (P =  .18). The mean 
age of HFRS patients with VTE was 71 years (SEM 1.7), and the 
age differed significantly to those patients who did not have a 
VTE (P < .001).
Extracellular Vesicle Tissue Factor Activity in Hemorrhagic Fever With 
Renal Syndrome Patients
Extracellular vesicle TF activity was significantly higher during 
early HFRS with 2 peaks at 4–6 and 16–18 DPDO compared 
with late HFRS (22–30 DPDO) (Figure 1). Furthermore, peak 
EVTF activity during HFRS was found to be significantly 
higher compared with follow-up (median 0.5 ng/L [IQR, 0.1–1] 
vs median 0 ng/L [IQR, 0–0.3], respectively; P < .001). The peak 
EVTF activity levels did not differ between females (mean 0.83; 
Table 1. Characteristics of the HFRS Patientsa
Characteristics
HFRS Patients 
n = 88 Reference Values
Demographic Data   
 Age, years 52.5 (40.25–63) NA
 Sex, n female/male (%) 54/34 (61.4/38.6) NA
 Hospital care, n (%) 67 (76.1) NA
 Days of hospital care 5 (3–8) NA
Clinical Laboratory Data   
 D-dimer (mg/L), max 1.03 (0.5–1.4) <0.02
 APTT (s−1), max 31.4 (29.4–34.4) 24–34 
 PT/INR, max 1 (1–1.2) <1.2
 Fibrinogen (g/L), max 4.96 (4.4–6.2) 2–3.9
 Platelets (×109 L), min 69.5 (44–90) 145–387
 Creatinine (µmol/L), max 201.5 (8113.5–375.3) 45–105
Biomarkers   
 EVTF (pg/mL), max 0.5 (0.1–1) NA
 PAI-1 (ng/mL), max 55.8 (39.4–85.9) NA
 tPA (ng/mL), max 36.2 (25.3–65.5) NA
Anticoagulation/thrombolysis treatment 11 (12.5%) NA
HFRS Disease Outcome   
 Intravascular coagulationb, n (%) 27 (30.7) NA
  -DIC, n (%) 24 (27.3) NA
  -VTE, n (%) 2 (2.3) NA
  -DIC and VTE, n (%) 1 (1.1%) NA
Abbreviations: APTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; EVTF, extracellular vesicle tissue factor; HFRS, hemorrhagic fever with renal syn-
drome; PAI-1, plasminogen activator inhibitor 1; PT/INR, prothrombin time converted to international normalized ratio; tPA, tissue plasminogen activator; max, maximum; min, minimum; 
NA, not applicable; VTE, venous thromboembolism.
aThe median and interquartile range of the age, peak, or nadir clinical variables is shown. The peak value is the maximum value obtained within 30 days of disease onset. Reference values 
are shown.
bIntravascular coagulation is defined as patients with either disseminated intravascular coagulation or venous thromboembolism. One HFRS patient developed their VTE after discharge, and 
diagnosis was first performed a few days after onset of symptoms; therefore, there were no laboratory data available to score for DIC.
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SEM 0.2) versus males (mean 0.84; SEM 0.2) (P = .994). Patients 
with HFRS were stratified into 2 groups below or above the me-
dian 52 years of age (n = 44 in each group) and the mean peak 
EVTF activity compared using the generalized linear model. 
There were no significant effects of age on peak EVTF activity 
(P = .16), although the older age group tended towards a higher 
peak EVTF activity compared with the younger age group 
(mean 1.1 [SEM 0.2] vs mean 0.6 [SEM 0.2], respectively). 
When testing for the effect on peak EVTF activity for age as 
a continuous variable using the generalized linear model, the 
association between age and peak EVTF was β = 0.02, P = .065, 
further indicating a trend towards increasing EVTF activity 
with age.
Kinetics of Clinical Coagulation and Fibrinolysis Markers During 
Hemorrhagic Fever With Renal Syndrome
Hemorrhagic fever with renal syndrome patients have throm-
bocytopenia during HFRS, which normalizes during the time 
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Figure 1. Extracellular vesicle tissue factor (EVTF) activity in hemorrhagic fever 
with renal syndrome (HFRS) patients. The kinetics of EVTF activity was calculated 
using the generalized estimating equation (GEE) method. The mean is displayed 
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Figure 2. Kinetics of clinical coagulation and fibrinolysis markers in hemorrhagic fever with renal syndrome (HFRS) patients. The kinetics of (A) platelets (109/L), (B) D-dimer 
(mg/L), (C) activated partial thromboplastin time ([APTT] s-1) (y-axis truncated at 22), (D) INR (y-axis truncated at 0.9) and (E) fibrinogen (g/l) was calculated using the general-
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course of HFRS (Figure 2A). D-dimer levels and APTT are 
significantly increased during early HFRS compared with late 
HFRS (Figure 2B and C). The APTT for one patient at day 28 
was excluded (APTT value: 128s−1) due to anticoagulation and 
thrombolysis after a mesenteric VTE, which was previously 
described in a case report [27]. Fibrinogen increases signifi-
cantly throughout HFRS peaking mid-phase to then normalize 
(Figure 2D).
Extracellular Vesicle Tissue Factor Activity Is Associated With Tissue 
Plasminogen Activator and Plasminogen Activator Inhibitor 1
To investigate the relationship between EVTF activity and other 
clinical and investigative coagulation markers in patients with 
HFRS, we used the GEE method including all samples within 
21 DPDO. There was no significant association between EVTF 
activity and either D-dimer, APTT, fibrinogen, or platelet count 
(Table 2). However, a strong positive association was found be-
tween EVTF activity and plasma levels of both tPA and PAI-1 
(Table 2).
Peak Extracellular Vesicle Tissue Factor Activity Increased in Hemorrhagic 
Fever With Renal Syndrome Patients With Intravascular Coagulation
Patients with HFRS were stratified into groups of those who 
had intravascular coagulation during HFRS (n = 27) and those 
who did not (n = 61). The mean and SEM for peak EVTF ac-
tivity was calculated and compared for difference between these 
2 groups using generalized linear models. The peak EVTF ac-
tivity level was significantly increased for HFRS patients that 
had intravascular coagulation compared with those who did not 
(Figure 3). When age and sex were included in the model, peak 
EVTF activity was still significantly increased in patients with 
intravascular coagulation (P  =  .021), and neither age nor sex 
had a significant impact (data not shown). The Supplementary 
Figure shows the graphs of peak EVTF activity in patients fur-
ther stratified into groups of DIC versus no DIC and groups of 
no VTE versus VTE. Extracellular vesicle tissue factor activity is 
significantly higher in patients with DIC or VTE compared with 
those patients who did not have DIC or VTE (Supplementary 
Figure). A  ROC curve analysis for intravascular coagulation 
showed AUC 0.634 (95% CI, 0.51–0.76; P  =  .046) with peak 
EVTF activity 0.51 pg/mL predicting intravascular coagulation 
with sensitivity 0.63 and specificity 0.61 (Figure 4).
Table 2. Association of EVTF Activity With Coagulation and Fibrinolysis 
Markersa
Markers of coagulation/fibrinolysis EVTF Activity (ng/L)
D-dimer (mg/L) β = 0.001 
P = .983
APTT (s−1) β = 0.272 
P = .359
PT/INR β = −0.016 
P = .11
Fibrinogen (g/L) β = −0.171 
P = .084
Platelets (×109/L) β = −7.964 
P = .106
PAI-1 (ng/mL) β = 4.889 
P = .004
tPA (ng/mL) β = 4.604 
P = .001
Statistical significances are displayed in bold.
Abbreviations: APTT, activated partial thromboplastin time; EVTF, extracellular vesicle tissue 
factor; PAI-1, plasminogen activator inhibitor 1; PT/INR, prothrombin time converted to in-
ternational normalized ratio.
aThe association between EVTF activity and coagulation and fibrinolysis markers were ana-
lyzed using the generalized estimating equation method. Only time points within 21 days 
postdisease onset are included in this analysis. The estimated β-coefficients corresponds 
to the change in dependent variable for 1 unit increase of EVTF.
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Figure 3. Extracellular vesicle tissue factor (EVTF) activity increased in patients 
with intravascular coagulation. The mean and standard error of the mean of peak 
EVTF activity in blood samples obtained from hemorrhagic fever with renal syn-
drome (HFRS) patients was calculated using the generalized linear model. The HFRS 
patients were stratified into groups of those who did not have intravascular coag-
ulation (n = 61) and those who did (n = 27). The peak EVTF activity was compared 
between these groups using the generalized linear model. *, P < .05.
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Figure 4. Peak extracellular vesicle tissue factor (EVTF) associated with intravas-
cular coagulation. A receiver operating characteristic curve analysis was performed 
using the peak EVTF value to predict intravascular coagulation.
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DISCUSSION
Patients with HFRS have an activated coagulation system, which 
is similar to other hemorrhagic fever viruses. In this study, we 
observed markedly elevated levels of plasma EVTF activity in 
HFRS patients within 21 days after onset of symptoms, with an 
early and a late peak. These findings support the notion that 
TF expression contributes to the systemic procoagulant state 
in this patient population. Consistent with a systemic proco-
agulant state, HFRS has previously been associated with other 
markers of systemic activation of coagulation, namely, throm-
bocytopenia and elevated D-dimer [28, 29]. In the present 
study, we did not observe a correlation between EVTF activity 
and D-dimer. However, we did observe an association between 
EVTF activity and tPA and PAI-1 levels. The increased levels of 
EVTF observed in the acute phase of PUUV-associated HFRS 
in this study are consistent with our recent observation that pa-
tients with Sin Nombre virus-associated HCPS have a signif-
icant transient elevation in plasma EVTF activity [15]. Levels 
of EVTF activity were almost 2-fold higher in HCPS patients 
compared with HFRS patients, which is consistent with more 
severe clinical syndromes in HCPS [15].
There is limited evidence of the cellular source of elevated TF 
activity associated with PUUV and hemorrhagic viruses more 
broadly. One of the primary target cells for orthohantavirus in-
fection is endothelial cells, and after PUUV infection TF and 
PAI-1 were expressed by endothelial cells [21]. Extracellular ves-
icle tissue factor activity was significantly associated with both 
PAI-1 and tPA levels in our study, suggesting that PUUV-infected 
endothelium may be a source of EVTF, PAI-1, and tPA. It is in-
teresting to note that other viruses, such as herpes simplex virus 
and dengue virus, have also been shown to increase TF expres-
sion in endothelial cells [14, 30]. However, monocytes and other 
immune cells could also be a likely source of elevated EVTF ac-
tivity levels in HFRS patients. In other hemorrhagic fever viruses, 
such as dengue and Ebola, increased monocyte TF expression 
has been reported [13, 31, 32]. Furthermore, lung macrophages 
from deceased HCPS patients also expressed TF and PAI-1 [33]. 
In addition, elevated plasma levels of EVTF activity have been 
observed in several other infectious diseases, such as hepatitis C 
and human immunodeficiency virus (HIV), and for patients with 
chronic HIV the levels of EVTF activity were associated with in-
creased immune cell activation [34, 35]. In our study, however, 
the levels of monocytes or other immune cells were not associated 
with EVTF activity levels (data not shown), although the number 
of monocytes does not necessarily equate to activation status. 
Therefore, monocytes and other immune cells could still be a 
source of EVTF in HFRS patients. The effect of orthohantaviruses 
infection on monocyte TF expression has yet to be reported.
Our previous studies suggest that HFRS patients are at an in-
creased risk of conditions associated with aberrant activation 
of coagulation, because HFRS was identified as a risk factor for 
arterial and VTE and approximately 30% of HFRS patients fulfill 
DIC criteria [18–20, 27]. Of note, we previously found an asso-
ciation between the endothelial glycocalyx degradation marker 
syndecan-1 with DIC in HFRS patients, indicating a crucial role 
of endothelial cells in coagulation during HFRS [36]. In cancer 
patients, the presence of DIC served as a strong predictor of both 
arterial and venous thrombosis in patients with cancer [24]; 
therefore, it is likely that HFRS patients that fulfill DIC criteria are 
at increased risk of VTE. We therefore combined HFRS patients 
that had had a VTE or fulfilled DIC criteria in this study. Of the 3 
HFRS patients with VTE, 2 fulfilled DIC criteria. It was not pos-
sible to determine when the third patient had their VTE because 
the patient developed symptoms after discharge from hospitaliza-
tion and diagnosis was not established before the next follow-up 
where several days had already passed. Therefore, there were no 
clinical laboratory data to score for DIC, although it is likely this 
patient would have fulfilled DIC criteria. We observed signifi-
cantly higher peak plasma levels of EVTF activity in patients who 
had intravascular coagulation compared with those that did not. 
Furthermore, in a ROC curve analysis, elevated levels of plasma 
EVTF activity served as a modest but significant predictor of in-
travascular coagulation. These data provide evidence of a formal 
association between elevated levels of EVTF activity and path-
ologies associated with intravascular coagulation. In other hem-
orrhagic fevers, TF expression on monocytes was significantly 
increased in patients with severe dengue fever in the acute phase 
of the disease compared with those with mild disease or healthy 
controls [14]. Furthermore, coagulation was attenuated and mor-
tality reduced in Ebola virus-infected rhesus macaques when the 
TF/factor VIIa complex was inhibited by recombinant nematode 
anticoagulant protein c2 [13]. These findings provide convincing 
evidence that TF-initiated coagulation plays a primary role in 
the pathophysiology of viral hemorrhagic fevers. Of note, in a 
previous study, we found that patients infected with influenza 
A subtype H1N1 had elevated levels of EVTF activity, and this 
was associated with mortality [37]. In our study, there were no 
fatalities after HFRS, and the case fatality rate after HFRS (0.4%) 
is considerably lower than for other hemorrhagic fever viruses 
[38]. However, in our previous epidemiological study in which 
we identified the causes of death in all HFRS patients diagnosed 
since 1997, we observed that cardiovascular causes of death were 
disproportionately higher during the first year after HFRS com-
pared with the Swedish population [39]. This, as well as the obser-
vation that patients with intravascular coagulation had increased 
levels of EVTF activity in our study, could indicate that EVTF 
activity is associated with cardiovascular sequelae after HFRS.
CONCLUSIONS
In conclusion, this study demonstrated a significant transient 
elevation in circulating levels of EVTF activity in patients with 
PUUV-associated HFRS in the first 21  days after symptom 
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onset. We propose that the rise in circulating EVTF activity re-
flects an increase in intravascular TF expression after PUUV 
infection that drives the activation of coagulation. We have also 
demonstrated that elevated plasma levels of EVTF activity are 
associated with DIC and VTE in patients with HFRS. It is in-
teresting to consider whether some patients with HFRS, and 
potentially other viral hemorrhagic fevers, would benefit from 
short-term thromboprophylaxis. Further clinical studies are 
needed before such recommendations could be implemented.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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